Formulation and in vitro evaluation of crisaborole-loaded solid lipid nanoparticles - topical system for atopic dermatitis

Read full text Summarise with VIRAT
Authors: Nisha Kalayil, Tularam Barot, Aarati Budar
Cited by: 0
References: 34

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Designing and testing a new way to deliver drugs through the skin using Solid Lipid Nanoparticles (SLNs) for sustained as well as enhanced topical delivery of Crisaborole. Methodology: Crisaborole was incorporated into SLNs using the Double Emulsification Solvent Evaporation Method. The SLNs were enhanced using a Box-Behnken design. The best-performing formulation was evaluated after optimization for particle size, etc, along with entrapment efficiency and in vitro release. Results: The SLNs exhibited a remarkable entrapment efficacy of 69.8 ± 1.1% to 80.6 ± 0.3%, and their particle size varied from 222.1 ± 8.5 nm to 440 ± 7.5 nm. In the in vitro release study of Crisaborole-SLNs, 92.7 ± 1.17 % was observed at 12 hours. The developed SLN formulation displays no significant change after three months of stability study under accelerated conditions. Conclusion: These results suggest that crisaborole-loaded solid lipid nanoparticles (SLNs) represent a promising vehicle for the topical delivery of crisaborole, with potential for enhanced dermal residence due to controlled release and nanoscale size within the skin, while minimizing systemic exposure.

Fields of Study & Subjects

Advancements in Transdermal Drug Delivery Advanced Drug Delivery Systems Nanoparticle-Based Drug Delivery

Publication details

Journal / source
Journal of Applied Pharmaceutical Research
Volume
14
Issue
2
Pages
203–212
Publication date
15 March 2026
Language
EN